ИСТИНА

Glioma is a heterogeneous group of primary brain tumors with poor prognoses. Effective treatment strategies for glioma have yet to be developed. This requires better understanding of molecular mechanisms involved into pathology, determining promising drug targets. Recently, it has become clear that mRNA stability regulation by Adenine-Uridine Rich Element (ARE) binding factors plays crucial role in cancer biology. Among ARE-binding factors TTP, BRF1, BRF2, KSRP but not HUR were upregulated at an mRNA level in brain tumors. Genes, correlating with ARE-factors by their expression patterns, split into two large subgroups: those that positively correlated with TTP and negatively correlated with HUR and vice versa. Interestingly, TTP-positive/HUR-negative genes were enriched in innate immune response mediators and TTP-negative/HUR-positive genes were enriched in RNA binding factors. Moreover, TTP associated genes were previously recognized as glioma survival prognosis markers. ARE-binding factors are involved into glioma biology on a transcriptome level, reveal antagonistic relations between TTP and HUR and indicate that an ARE-mediated mRNA stability control pathway represents a promising target for tumor treatment strategies development.